$2.50
1.19% today
Nasdaq, Jun 28, 06:51 pm CET
ISIN
US15673T1007
Symbol
IPSC

Century Therapeutics Inc Share price

$2.53
-0.51 16.78% 1M
-0.51 16.78% 6M
-0.79 23.80% YTD
-0.66 20.69% 1Y
-21.83 89.61% 3Y
-20.30 88.92% 5Y
-20.30 88.92% 10Y
Nasdaq, Closing price Thu, Jun 27 2024
ISIN
US15673T1007
Symbol
IPSC
Sector
Industry

Key figures

Market capitalization $213.79m
Enterprise Value $68.24m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 49.81
P/S ratio (TTM) P/S ratio 156.05
P/B ratio (TTM) P/B ratio 0.92
Sales growth (TTM) Sales growth -76.63%
Turnover (TTM) Turnover $1.37m
EBIT (operating result TTM) EBIT $-124.41m
Free cash flow (TTM) Free cash flow $-98.66m
Cash position $192.02m
EPS (TTM) EPS $-2.22
P/E ratio expected negative
P/S ratio expected 100.70
EV/Sales expected 32.14
Short interest 2.38%
Show more

Is Century Therapeutics Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Century Therapeutics Inc Share analysis

Unlock scores for free

Analyst opinions

5 Analysts have issued a Century Therapeutics Inc forecast:

4x Buy
80%
1x Hold
20%

Analyst opinions

5 Analysts have issued a Century Therapeutics Inc forecast:

Buy
80%
Hold
20%

Financial data from Century Therapeutics Inc

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
1.37 1.37
77% 77%
100%
- Direct costs 11 11
10% 10%
801%
-9.60 -9.60
132% 132%
-701%
- Selling and administrative expenses 16 16
18% 18%
1,155%
- Research and development costs 88 88
13% 13%
6,424%
-113 -113
4% 4%
-8,280%
- Depreciation and amortization 11 11
10% 10%
801%
EBIT (operating result) EBIT -124 -124
3% 3%
-9,081%
Net profit -133 -133
7% 7%
-9,742%

Figures in millions USD.

Don't miss a thing! We will send you all news about the Century Therapeutics Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Century Therapeutics Inc Share News

Positive
Seeking Alpha
8 days ago
Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythemat...
Neutral
GlobeNewsWire
25 days ago
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting
Neutral
GlobeNewsWire
about 2 months ago
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE)
More Century Therapeutics Inc News

Company profile

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Head office United States
CEO Brent Pfeiffenberger
Employees 165
Founded 2018
Website www.centurytx.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now